Mounjaro And Zepbound Power Eli Lilly’s 54% Revenue Jump In Q3, Hikes 2025 Forecast

All NewsOctober 30, 2025

Eli Lilly reported Q3 revenue of $17.6 billion, beating estimates and raising 2025 guidance as Mounjaro and Zepbound sales surged.

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent